

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4239-64129
Application Number	Not yet assigned. 10/615723
Filing Date	Concurrent herewith 7/8/2003
First Named Inventor	Zoon
Art Unit	Not yet assigned. 1647
Examiner Name	Not yet assigned. J. Seharaseyon

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Name
/JS/		4,569,908	2/11/1986	Mark
		4,716,217	12/29/1987	Caruthers
		4,758,428	7/19/1988	Mark
		4,806,347	2/21/1989	Leibowitz
		4,820,638	4/11/1989	Swetly
		4,885,166	12/5/1989	Meyer
		4,892,743	1/9/1990	Leibowitz
		4,914,033	4/3/1990	Bell
		4,917,887	4/17/1990	Hauptmann
		5,071,761	12/10/1991	Meyer
		5,089,400	2/18/1992	Meyer
		5,593,667	1/14/1997	Kung
		5,609,868	3/11/1997	Lowther

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Country
/JS/		0626448A	30 Nov 1994	EP

EXAMINER
SIGNATURE: /Jegatheesan Seharaseyon/

DATE
CONSIDERED: 03/20/2007

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	4239-64129
		Application Number	Not yet assigned. 10/615723
		Filing Date	Concurrent herewith 7/8/2003
		First Named Inventor	Zoon
		Art Unit	Not yet assigned. 1647
		Examiner Name	Not yet assigned. J. Seharaseyon
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS	
/JS/		Alexanko <i>et al.</i> , "Mapping of an epitope of human leukocyte alpha interferon A which is recognized by the murine monoclonal antibody NK2," <i>Biomed. Sci.</i> , 2(4):403-409, 1991	
		Alexanko <i>et al.</i> , "Reconstruction of an epitope capable of binding murine monoclonal antibodies NK2 within the sequence of human leukocyte interferon alpha F by site-directed mutagenesis," <i>Biochem. Biophys. Res. Commun.</i> , 169(3):1061-1067, June 29, 1990	
		Allen <i>et al.</i> , "Nomenclature of the Human Interferon Proteins," <i>J. Interferon Cytokine Res.</i> , 16:181-184, 1996	
		Di Marco <i>et al.</i> , "Mutational analysis of the structure-function relationship in interferon-alpha," <i>Biochem. Biophys. Res. Comm.</i> , 202(3):1445-1451, 15 August 1994	
		Fidler <i>et al.</i> , "Direct antiproliferative effects of recombinant human interferon-alpha B/D hybrids on human tumor cell lines," <i>Cancer Res.</i> , 47(8):2020-2027, April 15, 1987	
		Fish <i>et al.</i> , "Human leukocyte interferon subtypes have different antiproliferative and antiviral activities on human cells," <i>Biochem. Biophys. Res. Commun.</i> , 112(2):537-546, April 29, 1983	
		Goeddel <i>et al.</i> , "The structure of eight distinct cloned human leukocyte interferon cDNAs," <i>Nature, GB, Macmillan Journals Ltd. London</i> , 290:20-26, 5 March 1981	
		Horisberger and Di Marco, "Interferon-alpha hybrids," <i>Pharmac. Ther.</i> 66(3):507-534, 1995	
		Hu <i>et al.</i> , "Divergence of Binding, Signaling, and Biological Responses to Recombinant Human Hybrid IFN," <i>J. Immunol.</i> , 16(2):854-860, 15 July 1999	
		Horton <i>et al.</i> , "Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension," <i>Gene, NL, Elsevier Biomedical Press, Amsterdam</i> , 77:61-68, 1989	
		Hu <i>et al.</i> , "HuIFNalpha21 gene expression and properties of recombinant IFNalpha21," <i>J. Interferon Res.</i> , 14(suppl1):S98, September 1994	
✓		Meister <i>et al.</i> , "Biological activities and receptor binding of two human recombinant interferons and their hybrids," <i>J. Gen. Virol.</i> , 67(8):1633-1643, August 1986	

EXAMINER SIGNATURE:	/Jegatheesan Seharaseyon/	DATE CONSIDERED:	03/20/2007
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.			

[illegible]

EXAMINER SIGNATURE:	/Jegatheesan Seharaseyon/	DATE CONSIDERED:	03/20/2007
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			